Year-end Sale % OFF 
Abstract
At present, for the evaluation of patients with suspected acute coronary syndromes (ACS), currently available cardiac biomarkers depend on the presence of myocyte necrosis or left ventricular dysfunction in order to be diagnostic. With a better understanding of the pathophysiology that underlies the ACS has come a wide variety of candidate cardiac biomarkers, whose ability to detect the pathophysiologic processes involved in ACS may represent a step forward for the practicing clinician. Included among these novel biomarkers are markers of myocardial ischemia in the absence of necrosis (ischemia modified albumin and free fatty acids), markers of plaque inflammation and/or instability (myeloperoxidase, pregnancy-associated placental protein-A, whole blood choline, lipoprotein-associated phospholipase A2), as well as markers of platelet activity (soluble CD40 ligand). The potential role of these novel markers in the evaluation of patients with suspected ACS will be reviewed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Point of Care: The Journal of Near-Patient Testing & Technology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
